|
SYNLAB AG / Key word(s): Delisting SYNLAB AG: Cinven announces public delisting acquisition offer | Conclusion of Delisting Agreement 31-May-2024 / 08:40 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed a delisting agreement (“Delisting Agreement”) with Ephios Bidco GmbH, a subsidiary of Ephios Luxembourg S.à r.l., both holding companies controlled by investment funds advised by Cinven Limited.
Concurrently, Ephios BidCo GmbH announced its decision to make a public delisting acquisition offer to the shareholders of SYNLAB to acquire all shares outstanding of SYNLAB (“Offer”) not directly held by it. Ephios BidCo GmbH already holds approx. 86% of the voting rights in SYNLAB. The Offer will not be subject to any conditions. The Delisting Agreement provides that, subject to the review of the published offer document and within the scope of and in compliance with its legal obligations, SYNLAB will file an application for revocation of the admission of the SYNLAB shares to trading on the regulated market of the Frankfurt Stock Exchange prior to the expiry of the Acceptance Period. After the revocation of the listing has taken effect, SYNLAB’s shares will no longer be admitted to trading and traded on a domestic regulated market or a comparable market abroad. End of Inside Information 31-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Cryobiopsy and Forceps Biopsy Go Head-to-Head for Diagnosing Lung Lesions
As a supplement to standard needle aspiration for diagnosing lung lesions, cryobiopsy was no better than forceps biopsy for producing a definite diagnosis in a
January 10, 2024